

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Graham Griffiths
Date of last notice	5 December 2016

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Graham John Griffiths and Mrs Jillian Griffiths <Griffiths Private S/F A/C> Jillian Margaret Griffiths<Sunnycrest Investment A/C> (spouse and beneficiary)
Date of change	27 April 2018
No. of securities held prior to change	Mr Graham John Griffiths and Mrs Jillian Griffiths <Griffiths Private S/F A/C> 3,500,000 Ordinary Shares  Jillian Margaret Griffiths<Sunnycrest Investment A/C> 4,053,990 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company.
Class	Ordinary Shares
Number acquired	200,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$25,000

<b>No. of securities held after change</b>	<p>Mr Graham John Griffiths and Mrs Jillian Griffiths &lt;Griffiths Private S/F A/C&gt; 3,700,000 Ordinary Shares</p> <p>Jillian Margaret Griffiths&lt;Sunnycrest Investment A/C&gt; 4,053,990 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company.</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market acquisition

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	5 December 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	27 April 2018
No. of securities held prior to change	15,300,000 Ordinary Shares  8,107,979 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company.
Class	Ordinary Shares
Number acquired	200,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$25,000

<b>No. of securities held after change</b>	15,500,000 Ordinary Shares  8,107,979 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market acquisition

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Matthew Callahan
Date of last notice	4 July 2016

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Shenasaby Pty Ltd < Shenasaby Trust> (Mr Callahan is a beneficiary of this trust)
Date of change	27 April 2018
No. of securities held prior to change	Shenasaby Pty Ltd < Shenasaby Trust> 70,588,321 Ordinary Shares
Class	Ordinary Shares
Number acquired	149,986
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$18,748.25
No. of securities held after change	Shenasaby Pty Ltd < Shenasaby Trust> 70,738,307 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market acquisition

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

## Part 3 – <sup>+</sup>Closed period

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Robert Towner
Date of last notice	4 January 2017

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none"> <li>Austin 4 Pty Ltd ATF &lt;R&amp;S Towner Super A/C&gt;</li> <li>Austin 4 Pty Ltd Family Trust &lt;R&amp;S Towner Family A/C&gt;</li> </ul> <p><i>Relevant interests arise through shareholdings and directorships</i></p>
Date of change	27 April 2018
No. of securities held prior to change	<p>1,499,972 Ordinary Shares held by the following registered holders:</p> <ul style="list-style-type: none"> <li>749,986 Austin 4 Pty Ltd ATF &lt;R&amp;S Towner Super A/C&gt;</li> <li>749,986 Cornerstone Corporate Pty Ltd</li> </ul> <p>4,053,990 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company, held by Austin 4 Pty Ltd &lt;R&amp;S Towner Family Account&gt;</p>
Class	Ordinary Shares
Number acquired	Nil
Number disposed	749,986

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$93,748.25
<b>No. of securities held after change</b>	749,986 Ordinary Shares held by Austin 4 Pty Ltd ATF<R&S Towner Super A/C>  4,053,990 Unlisted Options, exercisable at \$0.0675 expiring 1 December 2019 and vesting progressively over three years at each 30 November, subject to continued service to the Company, held by Austin 4 Pty Ltd <R&S Towner Family Account>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Off market disposal

## Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – +Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A